Rothschild Investment Corp IL Sells 81,709 Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH)

Rothschild Investment Corp IL cut its holdings in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 95.9% during the third quarter, Holdings Channel reports. The fund owned 3,498 shares of the medical equipment provider’s stock after selling 81,709 shares during the period. Rothschild Investment Corp IL’s holdings in Zimmer Biomet were worth $480,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Zimmer Biomet by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 15,453,961 shares of the medical equipment provider’s stock valued at $1,819,550,000 after buying an additional 145,726 shares during the last quarter. Invesco Ltd. boosted its position in Zimmer Biomet by 45.5% in the 2nd quarter. Invesco Ltd. now owns 7,079,312 shares of the medical equipment provider’s stock valued at $833,519,000 after buying an additional 2,213,085 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Zimmer Biomet by 3.0% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,054,204 shares of the medical equipment provider’s stock valued at $712,822,000 after buying an additional 177,006 shares during the last quarter. Nuveen Asset Management LLC boosted its position in Zimmer Biomet by 3,725.2% in the 2nd quarter. Nuveen Asset Management LLC now owns 4,258,315 shares of the medical equipment provider’s stock valued at $501,374,000 after buying an additional 4,146,991 shares during the last quarter. Finally, Boston Partners boosted its position in Zimmer Biomet by 120.2% in the 2nd quarter. Boston Partners now owns 3,863,068 shares of the medical equipment provider’s stock valued at $454,952,000 after buying an additional 2,108,589 shares during the last quarter. Institutional investors and hedge funds own 87.83% of the company’s stock.

A number of research analysts have commented on the company. Credit Suisse Group increased their price objective on Zimmer Biomet from $101.00 to $120.00 and gave the company an “underperform” rating in a research report on Monday, July 29th. Canaccord Genuity upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and increased their price objective for the company from $137.00 to $167.00 in a research report on Wednesday, September 18th. Wells Fargo & Co increased their price objective on Zimmer Biomet from $150.00 to $158.00 and gave the company an “outperform” rating in a research report on Monday, September 9th. Jefferies Financial Group increased their price target on Zimmer Biomet from $150.00 to $167.00 and gave the company a “buy” rating in a research note on Monday, July 29th. They noted that the move was a valuation call. Finally, Oppenheimer increased their price target on Zimmer Biomet from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, July 29th. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. Zimmer Biomet currently has a consensus rating of “Buy” and a consensus price target of $145.40.

In related news, insider Didier Deltort sold 360 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $139.25, for a total transaction of $50,130.00. Following the sale, the insider now owns 1,194 shares of the company’s stock, valued at approximately $166,264.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Chad F. Phipps sold 7,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $138.28, for a total value of $967,960.00. Following the sale, the vice president now directly owns 37,722 shares in the company, valued at approximately $5,216,198.16. The disclosure for this sale can be found here. Insiders have sold a total of 40,391 shares of company stock worth $5,642,274 in the last ninety days. 0.72% of the stock is currently owned by company insiders.

Shares of Zimmer Biomet stock opened at $136.44 on Friday. The company has a market capitalization of $27.39 billion, a PE ratio of 17.86, a PEG ratio of 2.53 and a beta of 1.16. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $143.57. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The stock’s fifty day simple moving average is $137.14 and its 200 day simple moving average is $127.13.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Friday, July 26th. The medical equipment provider reported $1.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.02. The business had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The firm’s revenue was down .9% compared to the same quarter last year. During the same quarter last year, the business posted $1.92 EPS. Analysts predict that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.70%. The ex-dividend date is Friday, September 27th. Zimmer Biomet’s payout ratio is presently 12.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

See Also: What is a Lock-Up Period?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.